Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA May Scrap Clinical Study Report Disclosure For New Drug Approvals

Executive Summary

The pilot project former Commissioner Gottlieb championed found only one sponsor interested in participating.

You may also be interested in...



Clinical Study Report Release Could Compromise Patient Privacy, Groups Say

US FDA's plan to post CSRs may also inadvertently release confidential commercial information, agency is warned by industry groups.

US FDA's Integrated Review Document Would Dramatically Downsize Public Information

Interdisciplinary review template provides efficient summaries of data, but without the insight into regulatory thinking made possible by disclosure of decisional memoranda, subject area reviews, and meeting minutes.

Vocabulary Change: CDER Eliminating 'Review' For NDAs And BLAs

Like ANDA evaluations, US FDA plans to use the word assessment to describe them for NDAs and BLAs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel